ProKidney Corp. (PROK)
NasdaqCM · USD · Healthcare · Biotechnology
$1.36 (+0.00%) as of
Key statistics
- Market cap
- 542.89M
- Forward P/E
- -2.24
- EPS (TTM)
- -0.5300
- Dividend yield
- 0.00%
- 52-week range
- 1.3000 – 3.2700
- Beta
- 1.80
- Revenue (TTM)
- 818k
- Profit margin
- 0.00%
- Analyst target
- $6.90
- Volume
- 32.85k
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Winston-Salem, NC, United States
- Employees
- 231
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.